within Pharmacolibrary.Drugs.ATC.G;

model G03FA10
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.64,
    Cl             = 6.666666666666667e-07,
    adminDuration  = 600,
    adminMass      = 0.3 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.011666666666666665,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G03FA10</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Norgestrel and estrogen is a combined oral contraceptive agent containing the progestin norgestrel and an estrogen, typically ethinylestradiol. This combination is used primarily for prevention of pregnancy. While highly effective as a contraceptive, some formulations are less commonly used in current clinical practice compared to newer generation products.</p><h4>Pharmacokinetics</h4><p>Estimated average pharmacokinetics for oral administration of norgestrel 0.3 mg and ethinylestradiol 0.03 mg in healthy adult women based on available literature for component drugs; no direct population PK model for the fixed combination was identified.</p><h4>References</h4><ol><li><p>Moreira de Brito, C, et al., &amp; Cercato, C (2021). Pharmacokinetics of oral levonorgestrel and ethinylestradiol in women after Roux-en-Y gastric bypass surgery. <i>Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery</i> 17(4) 673–681. DOI:<a href=\"https://doi.org/10.1016/j.soard.2020.12.007\">10.1016/j.soard.2020.12.007</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33547015/\">https://pubmed.ncbi.nlm.nih.gov/33547015</a></p></li><li><p>Wang, X, et al., &amp; Malhotra, BK (2024). Assessment of the Effects of Abrocitinib on the Pharmacokinetics of Probe Substrates of Cytochrome P450 1A2, 2B6 and 2C19 Enzymes and Hormonal Oral Contraceptives in Healthy Individuals. <i>European journal of drug metabolism and pharmacokinetics</i> 49(3) 367–381. DOI:<a href=\"https://doi.org/10.1007/s13318-024-00893-5\">10.1007/s13318-024-00893-5</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38554232/\">https://pubmed.ncbi.nlm.nih.gov/38554232</a></p></li><li><p>Devineni, D, et al., &amp; Leung, AT (2007). Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive. <i>Journal of clinical pharmacology</i> 47(4) 497–509. DOI:<a href=\"https://doi.org/10.1177/0091270006297919\">10.1177/0091270006297919</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17389559/\">https://pubmed.ncbi.nlm.nih.gov/17389559</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G03FA10;
